Auf diese Chance haben wir viel zu lange gewartet!

Assets, tickers, and sectors mentioned

• UnitedHealth (UNH) — primary focus; large-cap health insurer
• Altcoins / crypto (separately mentioned)
• Pharmaceutical sector / drug manufacturers — cited as facing margin pressure
• Instruments / tools: stocks (spot), ETFs/portfolios (example: “US Titans” package), TradingView, MACD indicator
• Broker partner: Smartbroker Plus (affiliate recommendation)

Market / macro context

• Market awaiting a Fed statement from Jerome Powell (referenced time: 19:30 German time). Markets expected to be volatile depending on wording.
• Market-implied interest rates discussed in the ~350–375 basis point range (commentary on market pricing).
• Political / regulatory risk in the U.S. healthcare and pharma space cited as a driver of margin pressure and negative guidance for the sector (impacting UNH).

Current positioning and disclosures

• Presenter (Phantom) and his service are already invested in UNH (one tranche) inside a “US Titans” package and plan to increase exposure.
• Intent to dollar-cost average (DCA) with 3+ tranches.
• Affiliate referral to Smartbroker Plus for buying UNH; short-term chart details reserved for paid customers.
• No formal “not financial advice” phrase recorded; presenter discloses personal positions and subscription/affiliate asks (potential conflict of interest).

Technical / methodological framework

Timeframe and indicators

• Timeframe used: 2-week candles (each candle = two weeks).
• Main indicator: MACD on a 2-week chart.
  • How-to (tutorial-level): Open UNH on TradingView → Indicators → MACD (under Technicals).

Elliott Wave rules / read applied

• Identify corrective upward (3-part) structures and look for bearish divergence (price higher-high + MACD lower-high).
• Bearish divergence + MACD signal-line cross validated a prior top and subsequent sell-off.
• Expect a five-part downward impulse to complete the C of wave 2 (an over-cyclical correction).
• Most common bottom range for such a wave-2 correction: 61.8% – 78.6% Fibonacci retracement from the prior impulse; in weak environments could extend to 88.7%.
• Wave-4 invalidation rule: wave 4 must not enter the price territory of prior wave 1 — for UNH the stated invalidation level is > $437.70.

Bullish-reversal confirmation criteria

• A bullish MACD divergence at new lows: price makes a new low while MACD shows decreasing bearish momentum (higher low on MACD).
• Subsequent higher-high price action to confirm trend reversal (a positive MACD cross alone is not sufficient).

Risk / trade management approach

• DCA using multiple tranches (3+) to capture the defined bottom zone.
• Use conservative retracement targets (61.8%–78.6%) as primary buy zones; allow for extension to 88.7% if macro/earnings are very weak.
• Short-term exact entries and chart work are withheld for paying clients.

Key numbers, levels, price targets, timelines

• Current quoted price (approx): $288.70 (transcript showed “28870”, interpreted as ~$288.70). Presenter says he is near breakeven at that level.
• Previous peak used in the wave count (starting impulse): ~ $625.
• Over-cyclical bottom target (wave-5 internal target): $154 per share (presenter’s probable bottom for internal wave 5).
• Expected long-term bullish cycle target (wave-3 / 162% extension): $1,118 per share (presenter’s medium/long-term primary target).
  • Presenter framed this as a potential “total return of 426%” (note: presenter’s percentage arithmetic may be inconsistent with the stated levels).
• Invalidation level for the current wave-4 drop scenario: UNH above $437.70 would invalidate the bearish wave-4 interpretation.
• Fibonacci retracement band for base formation: 61.8% – 78.6% (primary buy zone); secondary possibility at 88.7%.
• Fed statement timing: same evening as the video (source of possible near-term volatility).

Risks, cautions, and caveats

• MACD is a trend-following tool and can give false signals during sideways markets; a positive MACD cross alone is not confirmation of a bullish trend.
• Bearish divergences can foreshadow reversals but may produce false signals.
• Political / regulatory actions and margin pressure in the health/pharma sector could push results lower and risk dividend cuts.
• Alternative scenario: if UNH trades above $437.70, the current wave count/impulse interpretation would be invalidated and a more complex corrective structure would be likely.
• Presenter bias: already invested and encouraging followers to use his partner broker (conflict of interest).

Explicit recommendations / actionable signals (presenter’s plan)

• Buy into the defined over-cyclical target zone via DCA with multiple tranches (3+).
• Primary buy zone: 61.8%–78.6% Fibonacci retracement; possible deeper buy at 88.7% if market/earnings are bad.
• Do not rely solely on a MACD positive cross — wait for bullish divergence plus higher-high price action for confirmation.
• Manage risk: monitor invalidation > $437.70 and be mindful of sector margin/dividend risk.

Performance / historical context cited

• UnitedHealth historically produced large long-term returns from IPO (presenter cited up to “76,000%” rally as an anecdote for buy-and-hold).
• Presenter claims prior Elliott+MACD analysis correctly anticipated UNH’s top and the subsequent sell-off.

Other practical notes

• Presenter demonstrates how to add MACD on TradingView (tutorial-level).
• Short-term exact entry/chart details and tactical levels are reserved for subscribers/paid customers.
• Promotional / engagement asks included (likes, subscribe, broker affiliate).

Presenters and sources cited

• Presenter: Phantom (Phantom channel / HKZM)
• Federal Reserve / Jerome Powell (macro context)
• TradingView (charting tool)
• Elliott Wave methodology (theory and rules referenced)
• Smartbroker Plus (affiliate broker partner)

Note: The video did not contain a formal “not financial advice” statement; disclosures consist of personal position and affiliate/subscription mentions.